21
TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical Center and University of Maryland - Baltimore

TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Embed Size (px)

Citation preview

Page 1: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

TSE Advisory Committee October 14, 2004, Silver Spring, MD

Removal of blood-borne TSE infectivity by leukoreduction filters

Luisa GregoriV.A. Medical Center and

University of Maryland - Baltimore

Page 2: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Distribution of infectivity in blood components

Plasma

BuffyCoat

RBC

ComponentVolume Infectivity

Recovered

InfectivityNormalized

25%

35%

20%

30%

45%

25%

70% WBC 60% platelets 14% plasma7-10% RBC

Page 3: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Infectivity in blood

• TSE infectivity is not associated with platelets.

• Infectivity unlikely to be associated with red

cells.

• Is infectivity uniquely associated with white

cells?

• Significant proportion of infectivity is found in

plasma.

Page 4: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Experimental tests of leukoreduction

• High speed centrifugation does not remove all

plasma infectivity.

• Filtration experiments with TSE infectivity

– Brown et al., 1999

– C.V. Prowse & A. Bailey, 2000

Page 5: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Summary

• Infectivity was not removed by the leukoreduction plasma filter tested.

• Spiked PrPres was not removed by the leukoreduction whole blood filters tested.

• Leukofiltration cannot be presumed to remove TSE infectivity without proof.

Page 6: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Leukoreduction conditions

• Endogenous TSE infectivity in blood

• No scale down - Full unit of scrapie hamster whole blood

• Use of the same protocol and equipment used in the blood centers in Canada

• Leukoreduction of two in-line Leukotrap filtration systems: whole blood and RC-PL

Page 7: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

WBF2

AS-3 PPP

[RBC]

Whole Blood

Leukoreduced Whole Blood

Platelet Poor Plasma

Leukoreduction Whole Blood Filtration

Whole Blood WBF2 Pall filter

Page 8: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Whole Blood

PL filter

RC filter

Leukoreduced

PPP

Leukoreduced

PC

AS-3

RBCPlatelet

Concentrate

Leukoreduction RC-PL Filtration

Platelets ATS and Red Cell RCM1 Pall filters

Page 9: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Hamster blood leukoreduction using human blood parameters

• Collection of a full unit (~ 450 mL) of scrapie infected hamster blood in a few hours.

• Blood processed within 8 hr from collection.

• At least 3 log of white cells must be removed by the filter.

• Cell recovery and level of white cells contamination within specifications. • A unit of leukoreduced RBC must contain at least 85% of

the original red cells and < 5 X 106 white cells.

AABB specifications

Page 10: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Leukofiltration validation

• Measured total blood cell count with cell

counter calibrated for hamster blood.

• Measured white cell count with manual count

and by flow cytometry.

• Did not measure cell fragmentation or

microvesicles generation. - Prowse et al. 1999.

Page 11: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Leukoreduction whole blood filtrationcell recovery

Volume (ml) WBC % rec

Log10

reduct RBC % rec Platelets % rec

WB pre 448.5 2.1E+09 100 0 3.7E+12 100 1.4E+11 100

WB post 424.2 3.0E+06 0.15 2.9 3.6E+12 100 1.5E+11 100

PPP 179 3.0E+05 0.02 3.8 0 0 1.1E+10 8RBC +AS3 305.9 2.0E+06 0.15 3 3.1E+12 86 1E+11 71

> 85%< 5 X 106

~ 3-log

Page 12: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

WBF2

AS-3 PPP

[RBC]

Whole Blood

Leukoreduced Whole Blood

Platelet Poor Plasma

Leukoreduction Whole Blood Filtration

Whole Blood WBF2 Pall filter

Titration 1pre filtration

Titration 2post filtration

Page 13: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Titration studies

• Titration of whole blood pre and post leukoreduction filtration

• Limiting dilution titration method

• ~ 100 animals for titration (~5 mL)

• Titration was completed after 566 days post inoculation

• Brain from every animal was analyzed by Western blot

Page 14: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Limiting Dilution Titration of Blood

Inoculationof 5 mL total

50 L each

44 infected of 100 Inoculated

44 infected of 5 mL Inoculated

Approx. 44/5 = 8.8 ID/mL

Poisson Correction

11.6 ± 0.7 ID/mL

Inoculate Donor Bleed

Incubate

Page 15: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Days post inoculation

0 100 200 300 400 500 600

Nu

mb

er o

f an

imal

s

Whole blood

Leukoreduced whole blood

Page 16: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Titration results566 days post inoculation

(post/pre)% ~ 58%

*Corrected with Poisson distribution

Sample volume

inoculated mL

total animals

inoculated

total animals infected

Titer* ID/mL

standard deviation

fractional distribution

of infectivity

Whole Blood

5.2 104 50 13.1 1.6 1

Leukoreduced Blood

5.4 108 34 7.6 1.2 0.58

Page 17: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Conclusions

• ~ 40% of infectivity was retained by the filter.

• Same percentage of infectivity found in the buffy coat fraction.

• Consistent with removal of TSE infectivity associated with white cells.

• Post leukoreduction infectivity is most likely in plasma.

• TSE infectivity is present in at least two forms: associated with white cells and in plasma.

• Infectivity did not “wash off” during filtration and filtration did not liberate infectivity.

Page 18: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Implications

• Leukoreduction is a necessary but not sufficient

to remove all blood-borne TSE infectivity.

• 5800 ID/unit of whole blood 3400 ID/unit of

leukoreduced whole blood.

• Post leukoreduction infectivity is not cell

associated.

• Need for additional methods to remove cell-free

infectivity.

Page 19: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

AcknowledgmentRohwer Lab

Ellen Elliott

Renee Kahn

Claudia MacAuley

Justin Duzsa

Dwayne Moore

Sean Carter

Fidel Gillin

Daryl Butler

Lee Preston

Johari Barnes

Health Canada and Canadian Blood Services

Tony Giulivi

Nancy McCombie

Doug Palmer

Paul Birch

Pall Corp. US and Canada

Sam Coker

Bonnie Quanbury-Duern

Page 20: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

Filtration of endogenous infectivity in Plasma

Filtration of plasma through 28 mm Pall Corp. PLF1

Experiment Conditions Specimen ID/mL

Challenge 18 - 58

Filtrate 4 - 30

Challenge 0 - 11

Filtrate 16 - 65

Challenge 8 - 47

Filtrate 6 - 46

Frozen/thawed plasma from clinically

affected mice

Frozen/thawed plasma from pre-

clinical infection

Fresh plasma from symptomatic mice

1

2

3

Brown, P., Cervenakova, L, McShane, L.M., Barber, P., Rubenstein, R., Drohan, W.N. (1999) Transfusion 39, 1169-1178.

Page 21: TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical

PrPsc removal by whole blood leukofilters

Removal of spiked PrPres and Leukocytes by Filtration

Whole Blood FilterPrPres Removal

Log10

Control Brain*

Baxter/Asahi 4.0 2.7 -0.4

Fresnius 3.6 3.1 0.2

Macopharma 4.3 2.5 0.3

Pall 4.5 3.5 0.2

Leukocyte

Removal Log10

Prowse C.V. and Bailey A. Vox Sang (2000) 79, 248

* 500 mL of whole blood spiked with 10 mL of microsomal fraction of 10% brain from 263K scrapie hamster